Itn-Inspire

new drug candidates often have off-target effects resulting in adverse events, thus representing a major limitation for drug r&d. safety pharmacology (sp) aims to detect, understand and reduce undesirable pharmacodynamic effects early-on. especially, cardiovascular (cv) toxicity is problematic, as it is the most prevalent reason for failure during preclinical development and remains a key reason for drug attrition during clinical development and beyond. this indicates current sp screens fail to detect a number of (late-onset) functional or structural cv toxicities. additionally, sp uses a significant number of laboratory animals, thereby creating opportunities for a better implementation of the 3rs. the vision of inspire is to advance and “inspire” sp by exploring new technological capabilities to addressing emerging cv safety concerns. hereto, inspire unites expertise from academic teams, technology-providers, pharmaceutical companies, regulators and hospitals to create a european tr